Evicenter
Dupixent (dupilumab) in Atopic dermatitis
Manufacturer
sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.
Prescribing information
Dupixent (opens in a new tab)
Questions
76
Last updated

All questions

Clinical trials: Dupixent (dupilumab) in atopic dermatitis

17 questions · 9 sources

SOLO 1 and SOLO 2

How effective is Dupixent alone for adults with atopic dermatitis (SOLO 1 and SOLO 2)?

CHRONOS

How effective is Dupixent with topical corticosteroids in adults at 16 weeks (CHRONOS)?

What are the 1-year Dupixent results in adults with atopic dermatitis (CHRONOS)?

“In CHRONOS, of the 421 subjects, 353 had been on study for 52 weeks at the time of data analysis. Of these 353 subjects, responders at Week 52 represent a mixture of subjects who maintained their efficacy from Week 16 (e.g., 53% of DUPIXENT IGA 0 or 1 responders at Week 16 remained responders at Week 52) and subjects who were non-responders at Week 16 who later responded to treatment (e.g., 24% of DUPIXENT IGA 0 or 1 non-responders at Week 16 became responders at Week 52). Results of supportive analyses of the 353 subjects in the DUPIXENT with concomitant TCS trial (CHRONOS) are presented in Table 19. Table 19: Efficacy Results (IGA 0 or 1) of DUPIXENT with Concomitant TCS at Week 16 and 52 in Adult Subjects with Moderate-to-Severe AD DUPIXENT 300 mg Q2W + TCS Placebo + TCS Number of Subjectsa 89 264 Responderb,c at Week 16 and 52 22% 7% Responder at Week 16 but Non-responder at Week 52 20% 7% Non-responder at Week 16 and Responder at Week 52 13% 6% Non-responder at Week 16 and 52 44% 80% Overall Responderb,c Rate at Week 52 36% 13% a In CHRONOS, of the 421 randomized and treated subjects, 68 subjects (16%) had not been on study for 52 weeks at the time of data analysis. b Responder was defined as a subject with an IGA 0 or 1 (“clear” or “almost clear”) and a reduction of ≥2 points on a 0-4 IGA scale. c Subjects who received rescue treatment or with missing data were considered as non-responders.” (opens the source at this quote in a new tab)

Note: The n values are the chart legends for the Week 52 EASI-75 analysis (skin clearance page) and the Week 52 itch analysis (itch page).

Itch relief

How fast does Dupixent relieve atopic dermatitis itch in adults (post hoc analysis)?

Maintenance of response

Does Dupixent keep working if adults continue it after 16 weeks (SOLO-CONTINUE)?

Note: The page also charts the proportion of patients with no flares through Week 52 in a post hoc analysis; those chart values are not quoted here.

Skin barrier

Does Dupixent improve skin barrier function in atopic dermatitis?

Pediatric efficacy

What percentage of children on Dupixent for atopic dermatitis reach clear or almost-clear skin?

How effective is Dupixent in adolescents with atopic dermatitis (AD-1526)?

How effective is Dupixent in children aged 6 to 11 with severe atopic dermatitis (AD-1652)?

How effective is Dupixent for atopic dermatitis in children 6 months to 5 years (AD-1539)?

How was Dupixent studied long term in children with atopic dermatitis (AD-1434)?

Note: The page presents EASI-75 and EASI-90 results through Week 152 as charts; those values are not quoted here.

Hands and feet

How effective is Dupixent for hand and foot atopic dermatitis (AD-HAFT)?

What was the safety of Dupixent for hand and foot atopic dermatitis (AD-HAFT)?

Skin of color

How well does Dupixent work for atopic dermatitis in skin of color (DISCOVER)?

Does Dupixent reduce postinflammatory hyperpigmentation in patients with skin of color?

Outcome measures

How was itch measured in the Dupixent atopic dermatitis trials?

How were EASI and IGA scored in the Dupixent atopic dermatitis trials?

“The Eczema Area and Severity Index (EASI) combines the severity of eczema signs and the extent of skin involvement to measure lesional signs of AD.9 The severity of each of 4 eczema signs is assessed on a scale of 0 to 39 The signs of eczema (erythema, edema/papulation, excoriation, and lichenification) are graded using a defined process by the extent to which the patient is affected The extent of lesions in each body region is evaluated9 The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6 Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more while head and neck are weighted the least Each region gets a total region score9: Severity Score x Area Score x Multiplier = Region Score The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.9,a An improvement of at least 75% in lesion extent and severity (EASI-75) from baseline is a clinically meaningful change.1 a In patients <8 years of age, the multipliers for the head and neck are 0.2, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.3. In patients ≥8 years of age, the multipliers for the head and neck are 0.1, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.4.9” (opens the source at this quote in a new tab)

On the page, select: How was extent and severity of skin lesions (EASI) assessed in DUPIXENT clinical trials?